β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ’ Press Releases
Date | Press release |
---|---|
2025-05-29 07:00:00 | Patritumab Deruxtecan Biologics License Application For Patients With Previously Treated Locally Advanced Or Metastatic Egfr-mutated Non-small Cell Lung Cancer Voluntarily Withdrawn Basking ridge, n.j. & rahway, n.j.--(business wire)--the biologics license application (bla) seeking accelerated approval in the u.s. for daiichi sankyo (tse: 4568) and merckβs (nyse: mrk), known as msd outside of the united states and canada, patritumab deruxtecan (her3-dxd) based on the herthena-lung01 phase 2 trial for the treatment of adult patients with locally advanced or metastatic egfr-mutated non-small cell lung cancer (nsclc) previously treated with two or more systemic therapies has. |
2025-05-27 13:24:00 | Merck Announces Third-quarter 2025 Dividend Rahway, n.j.--(business wire)--merck announces third-quarter 2025 dividend. |
2025-05-22 17:43:00 | Merck Showcases Innovation In Advanced Cancers And Rare Tumors At Asco 2025 Darmstadt, germany--(business wire)--merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 american society of clinical oncology (asco) annual meeting, may 31 to june 4 in chicago. the presentations include the phase 3 maneuver data for potentially best-in-class pimicotinib in the treatment of the rare tumor tgct, as well as data from both company- and investigator-sponsored studies highlighting the com. |
2025-05-22 06:45:00 | Merck To Participate In The Bernstein 41st Annual Strategic Decisions Conference Rahway, n.j.--(business wire)--merck to participate in the bernstein 41st annual strategic decisions conference. |
2025-05-21 08:15:00 | Merck Presents Positive Phase 2 Data For Enpatoran Demonstrating Reduction In Disease Activity In Patients With Cutaneous Lupus Erythematosus (cle) And Systemic Lupus Erythematosus (sle) With Active Lupus Rash Darmstadt, germany--(business wire)--not intended for uk-, us- or canada-based media merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel tlr7/8 inhibitor, demonstrating clinically meaningful reduction in disease activity in patients with cutaneous lupus erythematosus (cle) and systemic lupus erythematosus (sle) with active lupus rash. the findings are from cohort a of the phase 2 willow study (nct05162586). results will be. |
2025-05-16 06:45:00 |
|
2025-05-15 06:45:00 |
|
2025-05-14 17:15:00 |
|
2025-05-13 06:45:00 |
|
2025-05-12 01:00:00 |
|
2025-05-08 06:45:00 |
|
2025-05-07 06:45:00 |
|
2025-04-29 06:45:00 |
|
2025-04-28 02:13:00 |
|
2025-04-28 02:11:00 |
|

π° Browse additional press releases for Merck!
Sign up for free or log inπ Claim your free eBook: "The Checklist Value Investor β A Smarter Way to Pick Stocks"